January 21, 2016
Glenmark Pharmaceuticals entering $130M market with two new generic medicines
Glenmark Pharmaceuticals entering $130M market with Actavis’ Potassium Cholire capsules and generics of Warner Chilcott’s Loestrin tablets
Pharmaceuticals, Biotechnology and Life Sciences
Glenmark Pharmaceuticals entering $130M market with Actavis’ Potassium Cholire capsules and generics of Warner Chilcott’s Loestrin tablets
US FDA has given Lupin a go to market Blisovi Fe 1/20 Tablets and Blisovi 1.5/30 Tablets market generic versions of Warner Chilcott’s Loestrin Fe 1/20 Tablets and Loestrin Fe 1.5/30 Tablets.
Mylan’s subsidiaries were sued Warner Chilcott and Qualicaps in connection with the filing of an ANDA with the FDA for Mesalamine Delayed-release Capsules.